author-photo

Erika Paige Hamilton

Sarah Cannon Research Institute
Duke University

201

Papers

3273

Citations

Citation Trend

Filter By

Papers (133) Sort By

Journal Conference Others

Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (10)
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study.

2020 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (4)
317 A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
A phase 1 study of XMT-1536 in patients with solid tumors likely to express NaPi2b: A summary of dose escalation

2020
Show All
- Source
- Cite
- Save
Citations (1)
A phase I study evaluating COM701 monotherapy and in combination with nivolumab in patients with advanced solid malignancies.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Abstract PD1-05: Atezolizumab in combination with trastuzumab emtansine or with trastuzumab and pertuzumab in patients with HER2-positive breast cancer and atezolizumab with doxorubicin and cyclophosphamide in HER2-negative breast cancer: Safety and biomarker outcomes from a multi-cohort Phase Ib study

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
First-in-human phase I study of SY-5609, an oral, potent, and selective noncovalent CDK7 inhibitor, in adult patients with select advanced solid tumors.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Abstract CT146: RGX-104, a first-in-class immunotherapy targeting the liver-X receptor (LXR): Initial results from the phase 1b RGX-104 plus docetaxel combination dose escalation cohorts

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (2)
137O Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB)

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)